MedPath

Assessment of Insulin Sensitivity in Healthy Adults by a 13C-glucose Breath Test : Method Development and Validation

Not Applicable
Completed
Conditions
Insulin Sensitivity/Resistance
Registration Number
NCT06766617
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

The current research project aims to assess the insulin resistance (less sensitivity), from measures of insulin and glucose in response to a standard oral intake of glucose (standardized oral glucose tolerance test). For this, we wish to test and validate the method of glucose labelled 13-C (stable isotope) breath test in comparison with standardized methods to measure glucose and insulin. Comparative methods that will be used are measures of glycemia from venous blood withdrawal and continuous glucose measurement in the skin tissue (external face of the arm) using the Abbott's freestyle libre system.

Repeatability and reliability of the 13-C glucose breath test will be checked from repeated measures over time.

Detailed Description

The current research project aims to assess the insulin resistance (less sensitivity), from measures of insulin and glucose in response to a standard oral intake of glucose (standardized oral glucose tolerance test). For this, we wish to test and validate the method of glucose labelled 13-C (stable isotope) breath test in comparison with standardized methods to measure glucose and insulin. Comparative methods that will be used are measures of glycemia from venous blood withdrawal and continuous glucose measurement in the skin tissue (external face of the arm) using the Abbott's freestyle libre system.

Repeatability and reliability of the 13-C glucose breath test will be checked from repeated measures over time.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
7
Inclusion Criteria

Healthy male adults aged 18-40 Able to understand and to sign a written informed consent

Read More
Exclusion Criteria
  • EXCLUSION CRITERIA
  • Known type 1 or type 2 diabetes, by anamnesis
  • Family history of type 2 diabetes (parents)
  • History of gestational diabetes
  • Any other metabolic disease possibly impacting the postprandial glucose and insulin response (anamnesis)
  • Any medication impacting the energetic metabolism, to the opinion of the investigator
  • Pregnant or lactating women (anamnesis)
  • Smoking
  • Allergy or intolerance to any food or compound used in this study
  • Currently following a strict exercise program (more than three times per week) in order to either lose weight, gain muscle or reach competition standards for a chosen sport
  • Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
  • Currently participating or having participated in another clinical trial during the past month.
  • Volunteer who cannot be expected to comply with the protocol
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Primary Outcome Measures
NameTimeMethod
1) To assess the within-subjects variability and overall repeatability of the 13C-glucose breath test0 to 300 minutes, after oral administration

repeated measure of breath over the 3 visits.

Secondary Outcome Measures
NameTimeMethod
Compare the results of breath test and CGM with the classical indexes of insulin resistance after an oral glucose challenge (OGTT) containing a small amount of [U13C]-glucose.0 to 300 minutes, after oral adminstration

repeated measure over the 3 visits of breath, plasma and CGM values

Repeatability of the continuous glucose monitoring system (CGM)0 to 300 minutes, after oral adminstration

repeated measure over the 3 visits of breath, plasma and CGM values

Trial Locations

Locations (1)

Clinical innovation lab

🇨🇭

Lausanne, Switzerland

© Copyright 2025. All Rights Reserved by MedPath